| Literature DB >> 34810376 |
Maria Sotiropoulou1, Ioannis Katsaros1, Michail Vailas1, Irene Lidoriki1, George V Papatheodoridis2, Nikolaos G Kostomitsopoulos3, Georgia Valsami4, Alexandra Tsaroucha5, Dimitrios Schizas1.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease, affecting almost one-third of the general population and 75% of obese patients with type 2 diabetes. The aim of this article is to review the current evidence concerning the role of quercetin, a natural compound and flavonoid, and its possible therapeutic effects on this modern-day disease. Despite the fact that the exact pathophysiological mechanisms through which quercetin has a hepatoprotective effect on NAFLD are still not fully elucidated, this review clearly demonstrates that this flavonoid has potent antioxidative stress action and inhibitory effects on hepatocyte apoptosis, inflammation, and generation of reactive oxygen species, factors which are linked to the development of the disease. NAFLD is closely associated with increased dietary fat consumption, especially in Western countries. The hepatoprotective effect of quercetin against NAFLD merits serious consideration and further validation by future studies.Entities:
Keywords: Flavonoids; liver; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; quercetin
Mesh:
Substances:
Year: 2021 PMID: 34810376 PMCID: PMC8656328 DOI: 10.4103/sjg.sjg_249_21
Source DB: PubMed Journal: Saudi J Gastroenterol ISSN: 1319-3767 Impact factor: 2.485
Figure 1Multiple parallel hits hypothesis
In vivo studies involving quercetin and NAFLD
| Author | Year | Animal model | Mechanism of induced NAFLD | Effects | Mechanism of action |
|---|---|---|---|---|---|
| Yang | 2019 | C57BLKS/J/Lepdb/Lepdb ( | diabetic vs control mice | reduction in liver swelling, normalization of liver enzymes, and reduced hyperglycemia | antioxidation, antiinflammatory effect and improved lipid metabolism via activating FXR1/TGR5 signaling pathways |
| Liu | 2018 | C57BL/J | HFD | alleviated hepatic steatosis | enhancing frataxin-mediated PINK1/Parkin-dependent mitophagy |
| Zhu | 2018 | Sprague-Dawley rats | HFD | alleviated hepatic steatosis | hepatic VLDL assembly and lipophagy are the main targets of quercetin against NAFLD via the IRE1a/XBP1s pathway |
| Porras | 2017 | mice | HFD | Improved gut microbial balance and related gut-liver axis activation | reverted gut microbiota imbalance and related endotoxemia-mediated TLR-4 pathway induction |
| Shimizu | 2015 | Caco-2 cells | - | alleviated hepatic steatosis | mRNA levels of apolipoprotein B downregulated |
| Pisonero-Vaquero | 2015 | Mice | methionine-choline-deficient (MCD) diet | alleviated hepatic steatosis | phosphatidylinositol 3-kinase (PI3K)/AKT pathway modulation |
| Surapaneni | 2014 | Rats | HFD | alleviated hepatic steatosis | reducing the levels of CYP2E1 |
| Ying | 2013 | Gerbils | HFD | decreased levels TC, TG, LDL-C, ALT, AST | reduced levels of pro-inflammatory cytokines TNF-α and IL-6 |
| Jung | 2013 | C57BL/6J mice | HFD | reduction in liver weight and amount of triacylglycerols and lipid droplet | downregulated lipid metabolism-related genes Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1 and Fasn |
| Li | 2013 | HepG2 cells | - | alleviated hepatic steatosis | suppression of lipogenesis gene expression levels of SREBP-1c and FAS |
| Panchal | 2012 | rats | HFD | attenuated liver steatosis | down-regulation of NF-kB, up-regulation of Nrf2, increased expression of CPT1a |
| Marcolin | 2012 | C57BL/6J mice | methionine-choline-deficient (MCD) diet | lower degree of liver steatosis, reduction in oxidative stress | reduced proinflammatory and profibrotic gene expression and oxidative stress |
| Kobori | 2011 | C56BL/6J mice | HFD | Improved TG levels, thiobarbituric acid-reactive substances, glutathione levels and peroxisome proliferator-activated receptor α expression | expression of hepatic genes related to steatosis, such as peroxisome proliferator-activated receptor γ and sterol regulatory element-binding protein-1c normalized |
| Kobori | 2009 | mice | STZ-induced diabetic mice | increase in blood glucose levels, improved plasma insulin levels | inhibition of Cdkn1a expression |
| Casaschi | 2002 | human intestinal cell-line CaCo-2 | - | alleviated hepatic steatosis | inhibitor of intestinal apolipoprotein B secretion |
Figure 2Quercetin mediates the key pathological events in the procession of NAFLD